Deadline For Electronic Prescribing Puts Focus On Micro Cap Benefiting From The Changing Laws

Deadline For Electronic Prescribing Puts Focus On Micro Cap Benefiting From The Changing Laws

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, November 16, 2021

In 2018, California legislators passed Assembly Bill 2789 mandating electronic prescribing (e-prescriptions) starting January 1, 2022. With the deadline less than six weeks away, the California Dental Association (CDA) has begun endorsing iCoreRx, a HIPAA-compliant cloud-based platform by Software-as-a-Service company iCoreConnect, Inc. (OTCQB: ICCT) that fulfills the new e-prescription laws not only in California, but those sweeping across America.

Specifically, AB-2789 requires healthcare practitioners authorized to issue prescriptions to have the capability to transmit electronic data transmission prescriptions, and requires pharmacies to have the capability to receive those transmissions. The bill also requires those healthcare practitioners to issue prescriptions as an electronic data transmission prescription, unless specified exceptions are met.

The CDA is a preeminent dental association in America. Founded in 1870, the association has 27,000 dentists as members, or 14% of all dentists in the country. Getting an endorsement from the CDA for technology that meets new state requirements can certainly have lasting implications for iCoreConnect revenue streams and its tiny $19 million market capitalization.

iCoreRx is one of 15 SaaS enterprise solutions offered by iCoreConnect, all of which optimize different needs for healthcare providers. The company has a particular specialization in the dental market, where many of its products and services have received endorsements by leading organizations nationwide, including the Maryland Dental Association and Michigan Dental Association in the last three weeks.

Momentum is building for iCoreConnect, which can now add an endorsement from the biggest dental association in the world’s fifth biggest economy to its list of more than 70 agreements with state or regional healthcare associations across the U.S.

That momentum appears to be evident in the Company’s recent quarterly filing showing that third quarter financial results ending September 30, 2021, saw revenues increase by 158% while gross profit increased 269%, compared with the three months ended September 30, 2020. More info on the recently released financials can be viewed here.

“iCoreRx ensures compliance with the new law and creates a stronger workflow for our members,” said CDA President Dr. Judee Tippett-Whyte in a statement on the endorsement. “iCoreRx is one of the most complete solutions to bring every aspect of the prescription writing process into one easily accessible place,” she added, going on to emphasize that the service is cost effective because the design of iCoreRx means that each CDA dentist will only need one subscription for each DEA number, not one for each location they operate.

With iCoreRx, California dental providers can securely prescribe all medications, including controlled substances, from any location or on any device. The platform integrates with existing management software and comes with a bevy of benefits, such as viewing dispensed prescriptions, a built-in Lexicomp drug directory to view brand vs. generic, dosage and interactions with patients' other medications, and a feature to save “Doctor's Favorites” for commonly used medication sets, amongst other things. Doctors can check patient medication history for up to five years, and quickly and easily select medication and dosage information through a comprehensive drug directory.

Add-on options selected by the CDA include access to the California Controlled Substance Utilization Review and Evaluation System (CURES) prescription drug monitoring program and seamless Electronic Prescribing for Controlled Substances (EPCS).

“We are eager to provide CDA members across the state of California with practice management integration, prescription history information and one-click access to their state prescription monitoring program, CURES,” commented Robert McDermott, President and CEO of iCoreConnect.

--

iCoreConnect (OTCQB: ICCT) Full Corporate Write-Up: Click Here.

--

About AllPennyStocks.com:

AllPennyStocks.com Media, Inc., founded in 1999, is one of North America’s largest and most comprehensive small-cap / penny stock financial portals. With Canadian and U.S. focused penny stock features and content, the site offers information for novice investors to expert traders. Outside of the countless free content available to visitors, AllPennyStocks.com Pro (premium service) caters to traders looking for that trading edge by offering monthly stock picks, daily penny stock to watch trade ideas, market commentary and more.

As a result of its commitment to journalistic excellence and abundance of information in a particular area of equity investing (micro-cap investing) where there aren’t many credible sources of information, AllPennyStocks.com continues to have one of the largest audiences of micro-cap investors on the internet.


Copyright © 2021 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

AllPennyStocks.com has been compensated nineteen thousand dollars by the company for its efforts in presenting the ICCT profile on its web site and distributing it to its database of subscribers as well as other services. For a complete disclaimer, investors are encouraged to click here: https://www.allpennystocks.com/spotlight/1075/icoreconnect-inc

Other Penny Stock Movers

Shares of Biopharma Up After News of Uplisting
Expansion into Taiwan Markets Is Helping Shares of this Blockchain Firm
Mixed Shelf Filing Gives Micro Cap Delayed Boost
Most Popular
FREE Newsletter


Back to Top